THE IMPACT OF RISK STRATIFICATION BY EARLY BONE-MARROW RESPONSE IN CHILDHOOD T- ACUTE LYMPHOBLASTIC LEUKAEMIA (A SINGLE INSTITUTION EXPERIENCE IN AZIZA OTHMANA HOSPITAL, TUNIS, TUNISIA).
EHA Library, Ben Abdennebi Yosr,
324056
RETROSPECTIVE ASSESSMENT OF TREATMENT PATTERNS AND RESOURCE UTILIZATION FOR PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA IN CANADA, UK, FRANCE, GERMANY, ITALY, AND SPAIN
EHA Library, Manasee V. Shah,
324073
A PHASE 1 STUDY OF NKX101, AN ALLOGENEIC CAR NATURAL KILLER (NK) CELL THERAPY, IN SUBJECTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS)
EHA Library, Carlos Bachier,
324096
ESCALADE: ACALABRUTINIB + RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN UNTREATED NON-GERMINAL CENTER B-CELL–LIKE (NON-GCB) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Library, Laurie Sehn,
324114
FRONT-MIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING EFFICACY AND SAFETY OF R-CHOP + TAFASITAMAB + LENALIDOMIDE VS R-CHOP ALONE FOR NEWLY-DIAGNOSED HIGH-RISK DLBCL
EHA Library, Umberto Vitolo,
324131